Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perjeta SC Dose-Finding Study
NCT02738970Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2016
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of pertuzumab in breast cancer (11 arms), sponsored by Roche. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity at 24 months, Maximum Serum Concentration at 24 months and 2 more. Started Jun 2016; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02738970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738970.